J&J Execs Reassure Shareholders On Quality Issues

Johnson & Johnson shareholders, upset over the health giant's battered image amid unprecedented product recalls and ethical lapses, peppered its new CEO with questions and criticism during J&J's annual meeting.

Others among the 1,800 shareholders attending raised concerns over serious side effects of some J&J prescription medicines.

Outgoing CEO Bill Weldon, who's stepping down after a decade, and successor Alex Gorsky went to great lengths to reassure the audience that the company is resolving its quality problems and focused on helping patients.

Gorsky says J&J has implemented new quality procedures and is confident it's resolving the problems that have led to about 30 recalls of consumer health products, hip replacements and prescription drugs.

Filed Under: Johnson & Johnson

Categories: New Jersey News